Business / Finance RSS Feed - Business / Finance

Beaumont Health joins UHC and Novation to increase cost savings, improve supply chain performance

Beaumont Health joins UHC and Novation to increase cost savings, improve supply chain performance

UHC announced today that Beaumont Health has partnered with UHC and its supply contracting company, Novation, on a new two-year initiative designed to increase cost savings and supply chain performance improvement. [More]
Funding helps researchers to kiss MS goodbye

Funding helps researchers to kiss MS goodbye

Murdoch University researchers have received funding to investigate the link between the Epstein-Barr virus infection, more commonly known as glandular fever or the ‘kissing disease’, and the debilitating disease Multiple Sclerosis (MS). [More]
Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

Confluence is a biopharmaceutical company focused on developing therapeutic treatments for Fragile X Syndrome and Autism Spectrum Disorders. AOP is an Austrian based company specializing in the development and marketing of medicines for rare and complex diseases. [More]
Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced operational, clinical and financial results for the year ended December 31, 2014. [More]
GenVec reports record financial results for Q4 and fiscal year 2014

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013. [More]
Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. [More]
Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. [More]

Affiliate of American Securities enters into definitive agreement to recapitalize Aspen Dental

American Securities LLC, Ares Management, L.P., and Leonard Green & Partners, L.P. today announced that an affiliate of American Securities has entered into a definitive agreement to recapitalize Aspen Dental Management Inc. in partnership with the management team and funds affiliated with Ares and Leonard Green. Terms of the transaction were not disclosed. [More]
Bruker’s new Wine and Honey screeners deliver easy, comprehensive cost efficient analysis

Bruker’s new Wine and Honey screeners deliver easy, comprehensive cost efficient analysis

The inherent ease of use allows non-expert users to conduct analyses from measurement to final report in minutes and without chromatography. [More]
Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis. [More]
OrthoSensor raises $19 million in Series C Preferred Stock financing

OrthoSensor raises $19 million in Series C Preferred Stock financing

OrthoSensor, Inc., the leader in Sensor-Assisted Surgery, announced today that it has raised $19 million in a private placement of Series C Preferred Stock. Bridger Healthcare, Ltd. and The Tullis Growth Fund, L.P. participated in the round. The proceeds will be used to drive the commercialization of VERASENSE, OrthoSensor's leading product, and expand product development activities. [More]

Everyday Health announces acquisition of Cambridge BioMarketing Group

Everyday Health, Inc., a leading provider of digital health and wellness solutions, today acquired Cambridge BioMarketing Group, LLC, the leader in strategic launch and marketing solutions for orphan and rare disease products. [More]
Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. [More]
GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec, Inc. today announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology. [More]
Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

Eli Lilly and Company and Innovent Biologics, Inc. today announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company. [More]
96-well glass vial storage plate for UHPLC

96-well glass vial storage plate for UHPLC

Porvair Sciences glass vial storage plate combines 96 borosilicate glass vials of 700µl into a rigid polypropylene carrier microplate to provide a superior product for storage and transportation applications. [More]

Allscripts to market NoteSwift 2.0 for Allscripts Professional EHR

NoteSwift, Inc. and Allscripts have entered into an agreement for Allscripts to market and resell NoteSwift 2.0 for Allscripts Professional EHR. In response to customer demand, this strategic agreement may help providers reduce the time spent on creating patient documentation by more than half through the use of medical speech recognition. [More]

INTEGRA Biosciences announces opening of German subsidiary

Following on from the successful launch of subsidiaries in France, the UK and the USA - INTEGRA Biosciences has announced the opening in January 2015 of a new organisation based in Konstanz, Germany. [More]
AbbVie signs exclusive worldwide license agreement with C2N for Alzheimer's disease therapies

AbbVie signs exclusive worldwide license agreement with C2N for Alzheimer's disease therapies

AbbVie today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. [More]
Antech Diagnostics agrees to acquire assets of AVRL for $21 million from Abaxis

Antech Diagnostics agrees to acquire assets of AVRL for $21 million from Abaxis

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, and VCA Inc., a leading animal healthcare company in the United States and Canada, today jointly announced Antech Diagnostics, Inc., VCA's laboratory division, has agreed to acquire the assets of AVRL (Abaxis Veterinary Reference Laboratory) from Abaxis for $21 million in cash. [More]
Advertisement
Advertisement